Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | CCR4 | P51679 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709543 | 0.92 | GHSR (0.57) | GHSRCCR4HTR6MEN1KMT2A | |
| SCHEMBL10121930 | 0.91 | GHSR (0.52) | GHSRCCR4 | |
| SCHEMBL1709622 | 0.91 | GHSR (0.52) | GHSRCCR4HTR6 | |
| SCHEMBL10121951 | 0.90 | GHSR (0.62) | GHSRHTR6 | |
| SCHEMBL1709601 | 0.89 | GHSR (0.54) | GHSRCCR4HTR6MEN1KMT2A | |
| SCHEMBL10122112 | 0.86 | GHSR (0.64) | GHSRCCR4HTR6CA12CA1 | |
| SCHEMBL1709712 | 0.85 | GHSR (0.53) | GHSRCCR4HTR6MEN1KMT2A | |
| SCHEMBL1994659 | 0.84 | GHSR (0.58) | GHSRCCR4HTR6KMT2ACYP19A1 | |
| SCHEMBL1709653 | 0.83 | GHSR (0.53) | GHSRCCR4MEN1KMT2A | |
| SCHEMBL10121922 | 0.83 | GHSR (0.58) | GHSRCCR4CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885CCR4 3489/4885HTR6 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.